Potential of plant-derived natural products in the treatment of leukemia and lymphoma

Current Drug Targets

Volumn 11, Issue 7, 2010, Pages 812-822

  Lucas, David M ^a,b   Still, Patrick C ^b   Bueno Pérez, Lynette ^b   Grever, Michael R ^a   Douglas Kinghorn, A ^b  

^a Department of Surgery   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Epipodophylloxin derivatives; Flavopiridol; Hematological malignancies; Leukemia; Lymphoma; Natural products; Silvestrol; Vinca alkaloids

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BRUCEANTIN; CEPHALOTAXINE; CYTARABINE; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOFOS; ETOPOSIDE; FLAVOPIRIDOL; HOMOHARRINGTONINE; HONOKIOL; INDIRUBIN; MAYTANSINOID DERIVATIVE; MEISOINDIGO; MITOXANTRONE; NATURAL PRODUCT; NAVELBINE; NOSCAPINE; PLANT EXTRACT; PODOPHYLLOTOXIN DERIVATIVE; PODOPHYLLUM EMODI EXTRACT; SILVESTROL; TENIPOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCA ALKALOID; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; B CELL LEUKEMIA; BLADDER CANCER; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CEPHALOTAXUS; CHINESE MEDICINE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; HEMATOLOGIC MALIGNANCY; HIGHER PLANT; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIPLE MYELOMA; MYALGIA; NONHODGKIN LYMPHOMA; NONHUMAN; PODOPHYLLUM; PODOPHYLLUM EMODI; STRUCTURE ACTIVITY RELATION; TESTIS CANCER; TRADITIONAL MEDICINE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL PRODUCTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA; LYMPHOMA; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; TRITERPENES;

EID: 77954695641     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791320809     Document Type: Article

References (123)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Kinghorn AD. In: Lemke, T and Williams, DA Eds., Foye's Principles of Medicinal Chemistry. Baltimore, Wolters Kluwer/Lippincott Williams & Wilkins 2008; 12-25.
3. Williams DH, Stone MJ, Hauck PR, Rahman SK. Why are secondary metabolites (natural products) biosynthesized? J Nat Prod 1989; 52: 1189-208.
4. Noble RL. Vincaleukoblastine. Can Med Assoc J 1961; 85: 610-1.
5. Noble RL, Beer CT, Cutts JH. Further biological studies of vincaleukoblastine - an alkaloid isolated from Vinca rosea (L.). Biochem Pharmacol 1958; 1: 347-8.
6. Svoboda GH, Neuss N, Gorman M. Alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don.). V. Preparation and characterization of alkaloids. J Am Pharm Assoc 1959; 48: 659-66
7. Johnson IS, Wright HF, Svoboda GH, Vlantis J. Antitumor principles derived from Vinca rosea Linn. I. Vincaleukoblastine and leurosine. Cancer Res 1960; 20: 1016-22.
8. Svoboda GH. Alkaloids of Vinca rosea (Cathanthus roseus) V. Preparation and characterization of alkaloids. Lloydia 1961; 24: 173-80.
9. Cutts JH. The effect of vincaleukoblastine on dividing cells in vivo. Cancer Res 1961; 21: 168-72.
10. Neuss N, Gorman M, Boaz HE, Cone NJ. Vinca alkaloids. XI. Structures of leurocristine and vincaleukoblastine. J Am Chem Soc 1962; 84: 1509-10.
11. Cutts JH, Beer CT, Noble RL. Biological properties of vincaleukoblastine, an alkaloid in Vinca rosea Linn. with reference to its antitumor action. Cancer Res 1960; 20: 1023-31.
12. Karon M, Freireich EJ, Frei E, et al. The role of vincristine in the treatment of childhood acute leukemia. Clin Pharmacol Ther 1966; 7: 332-9.
13. Chabner BA, Amrein PC, Druker BJ, et al. In: Brunton LL, Lazo JS, Parker KL, Eds., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition. New York; McGraw-Hill 2006; 1257-62.
14. Guérritte F, Fahy J. In: Cragg GM, Kingston DGI, Newman DJ, Eds., Anticancer Agents from Natural Products. Boca Raton FL, CRC/Taylor & Francis 2005; 123-35.
15. Dancey J, Steward WP. The role of vindesine in oncology recommendations after 10 years' experience. Anticancer Drugs 1995; 6: 625-36.
16. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994; 5: 817-20.
17. Diehl V, Re D, Harris NL, PM M. In: DeVita, VT, Lawrence, TS and Rosenberg, SA Eds., Cancer: Principles and Practice of Oncology, 8th Ed. Philadelphia, Williams & Wilkins, 2008; 2167-220.
18. Canel C, Moraes RM, Dayan FE, Ferreira D. Podophyllotoxin. Phytochemistry 2000; 54: 115-20.
19. Hartwell JL, Schrecker AW. Components of podophyllin. V. The constitution of podophyllotoxin. J Am Chem Soc 1951; 73: 2909-16.
20. van Maanen JMS, Retèl J, de Vries J, Pinedo HM. Mechanism of action of the antitumor drug etoposide: a review. J Nat Cancer Inst 1988; 80:526-33.
21. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34: 1514-21.
22. Lee K-H, Xiao Z. In: Cragg, GM, Kingston, DGI and Newman, DJ Eds., Anticancer Agents from Natural Products. Boca Raton, FL, CRC/Taylor & Francis, 2005; 71-87.
23. Itokawa H, Wang X, Lee K-H. In: Cragg, GM, Kingston, DGI and Newman, DJ Eds., Anticancer Agents from Natural Products. Boca Raton, FL, CRC/Taylor & Francis, 2005; 47-70.
24. Kantarjian HM, Talpaz M, Santini V, et al. Homoharringtonine: history, current research, and future direction. Cancer 2001; 92: 1591-605.
25. Powell RG, Weisleder D, Smith CR Jr. Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity. J Pharm Sci 1972; 61: 1227-30.
26. Paudler WW, Kerley GI, McKay J. Alkaloids of Cephalotaxus drupacea and Cephalotaxus fortunei. J Org Chem 1963; 28: 2194-7.
27. Abraham DJ, Rosenstein RD, McGandy EL. Structure of cephalotaxine and related alkaloids. Tetrahedron Lett 1969; 4085-6.
28. Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother 1977; 12: 298-300.
29. Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977; 72: 323-30.
30. Visani G, Russo D, Ottaviani E, et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on in vitro growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 1997; 11: 624-8.
31. Takemura Y, Ohnuma T, Chou TC, Okano T, Holland JF. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother Pharmacol 1985; 14: 206-10.
32. Boyd AW, Sullivan JR. Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug harringtonine. Blood 1984; 63: 384-92.
33. Zhou JY, Chen DL, Shen ZS, Koeffler HP. Effect of homoharring tonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990; 50: 2031-5.
34. Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M. Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst 1988; 80: 1095-103.
35. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322-6.
36. O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999; 93: 4149-53.
37. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 2004; 130: 627-35.
38. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002; 43: 1763-8.
39. Marko D, Schatzle S, Friedel A, et al. Inhibition of cyclin dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 2001; 84: 283-9.
40. Du D, Ceng Q. Effect of indirubicin on the incorporation of isotope related precursors into nucleic acid and protein of tumor tissues. Zhong Cao Yao 1981; 12: 406-9.
41. Gan WJ, Yang T, Wen S, et al. Studies on the mechanism of indirubicin action in treatment of chronic myelocytic leukemia (CML). II. 5'-Nucleotidase in the peripheral white blood cells of CML. Chin Acad Med Sci Beijing 1985; 6: 611-3.
42. Harmon AD, Weiss U, Silverton JV. The structure of rohitukine, the main alkaloid of Amoora rohituka (syn. Aphanamixus polystachya) (Meliaceae). Tetrahedron Lett 1979; 721-4.
43. Newman DJ, Cragg GM. In: Cragg, GM, Kingston, DGI and Newman, DJ Eds., Anticancer Agents from Natural Products. Boca Raton, FL, CRC Taylor & Francis, 2005; 553-71.
44. de Azevedo WF Jr, Canduri F, da Silveira NJ. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002; 293: 566-71.
45. Billard C, Kern C, Tang R, Ajchenbaum-Cymbalista F, Kolb JP. Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17: 2435-43.
46. Hussain SR, Lucas DM, Johnson AJ, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 2008; 111: 3190-9.
47. Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91: 2482-90.
48. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005; 11: 4176-81.
49. Flinn IW, Byrd JC, Bartlett N, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005; 29: 1253-7.
50. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404.
51. Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 2005; 11: 8403-12.
52. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol,cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007; 13: 4467-73.
53. Fathi AT, Karp JE. New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep 2009; 11: 346-52.
54. Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 2004; 52: 1-26.
55. Kupchan SM, Komoda Y, Court WA, et al. Maytansine, a novelantileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 1972; 94: 1354-6.
56. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975; 189: 1002-5.
57. Wolpert-Defilippes MK, Adamson RH, Cysyk RL, Johns DG. Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide. Biochem Pharmacol 1975; 24: 751-4.
58. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992; 55: 31-51.
59. Rai SS, Wolff J. Localization of the vinblastine-binding site on beta-tubulin. J Biol Chem 1996; 271: 14707-11.
60. Kupchan SM, Komoda Y, Branfman AR, Dailey RG Jr. Tumor inhibitors. 96. Novel maytansinoids. Structural interrelationships and requirements for antitumor activity. J Am Chem Soc 1974; 96: 3706-8.
61. Kupchan SM, Komoda Y, Thomas GJ, Hintz HPJ. Maytanprine and maytanbutine, new antileukemic ansa macrolides from Maytenus buchananii. J Chem Soc Chem Commun 1972; 1065.
62. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 2008; 25: 475-516.
63. Ravry MJ, Omura GA, Birch R. Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. Am J Clin Oncol 1985; 8: 148-50.
64. www.clinicaltrials.gov; Accessed October 2009.
65. Liu Z, Floss HG, Cassady JM, Chan KK. Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2005; 40: 389-99.
66. Jautelat R, Brumby T, Schafer M, et al. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. Chembiochem 2005; 6: 531-40.
67. Wang Y, Zhu X, Xiao Z, et al. Inducing effect of mesindigo on apoptosis of leukemia cell line HL-60 and its mechanisms. Aizheng 2005; 24: 1464-8.
68. Weng Y, Liu B, Peng Z, Xiao, Z. Effects of mesindigo on acute promyelocytic leukemia cell line NB4 cells in vitro. Baixuebing Linbaliu 2005; 14: 136-9.
69. Cooperative Study of Phase III Clinical Trial on Meisoindigo, Tianjin, People's Republic of China. Zhonghua Xueyexue Zazhi 1997; 18: 69-72.
70. Robbers JE, Speedie MK, Tyler VE. Pharmacognosy and Pharmacobiotechnology. Baltimore MD, Williams & Wilkins, 1996.
71. Ke Y, Ye K, Grossniklaus HE, et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49: 217-25.
72. Ye K, Ke Y, Keshava N, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 1998; 95: 1601-6.
73. Landen JW, Lang R, McMahon SJ, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2002; 62: 4109-14.
74. Aneja R, Vangapandu SN, Lopus M, et al. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006; 69: 1801-9.
75. Barken I, Geller J, Rogosnitzky M. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res 2008; 28: 3701-4.
76. Kupchan SM, Britton RW, Lacadie JA, Ziegler MF, Sigel CW. The isolation and structural elucidation of bruceantin and bruceantinol, new potent antileukemic quassinoids from Brucea antidysenterica. J Org Chem 1975; 40: 648-54.
77. Kupchan SM, Britton RW, Ziegler MF, Sigel CW. Bruceantin, a new potent antileukemic simaroubolide from Brucea antidysenterica. J Org Chem 1973; 38: 178-9.
78. Cuendet M, Pezzuto JM. Antitumor activity of bruceantin: an old drug with new promise. J Nat Prod 2004; 67: 269-72.
79. Mata-Greenwood E, Cuendet M, Sher D, et al. Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. Leukemia 2002; 16: 2275-84.
80. Cuendet M, Christov K, Lantvit DD, et al. Multiple myeloma regression mediated by bruceantin. Clin Cancer Res 2004; 10: 1170-9.
81. Pettit GR, Cragg GM, Herald DL, Schmidt JM, Lohavanijaya P. Antineoplastic agents. 84. Isolation and structure of combretastatin. Can J Chem 1982; 60: 1374-6.
82. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987; 50: 119-31.
83. Pinney KG, Jelinek C, Edvardsen K, Chaplin DJ, Pettit GR. In: Cragg, GM, Kingston, DGI and Newman, DJ, Eds., Anticancer Agents from Natural Products. Boca Raton, FL, CRC Taylor & Francis, 2005; 23-46.
84. Fang L, He Q, Hu Y, Yang B. MZ3 induces apoptosis in human leukemia cells. Cancer Chemother Pharmacol 2007; 59: 397-405.
85. Petit I, Karajannis MA, Vincent L, et al. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 2008; 111: 1951-61.
86. Fujita M, Itokawa H, Sashida Y. Honokiol, a new phenolic compound isolated from the bark of Magnolia obovata. Chem Pharm Bull 1972; 20: 212-3.
87. Bai X, Cerimele F, Ushio-Fukai M, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 2003; 278: 35501-7.
88. Battle TE, Arbiser J, Frank DA. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 2005; 106: 690-7.
89. Ishitsuka K, Hideshima T, Hamasaki M, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 2005; 106: 1794-800.
90. Luo Y, Xu Y, Chen L, et al. Semi-synthesis and anti-proliferative activity evaluation of novel analogues of honokiol. Bioorg Med Chem Lett 2009; 19: 4702-5.
91. King ML, Chiang CC, Ling HC, et al. X-ray crystal structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia. J Chem Soc Chem Commun 1982; 1150-1.
92. Rose WC, Schurig JE, Meeker JB. Correlation of in vitro cytotoxicity with preclinical in vivo antitumor activity. Anticancer Res 1988; 8: 355-67.
93. Bohnenstengel FI, Steube KG, Meyer C, et al. Structure activity relationships of antiproliferative rocaglamide derivatives from Aglaia species (Meliaceae). Z Naturforsch [C] 1999; 54: 55-60.
94. Bohnenstengel FI, Steube KG, Meyer C, et al. 1H-cyclopenta[b]benzofuran lignans from Aglaia species inhibit cell proliferation and alter cell cycle distribution in human monocytic leukemia cell lines. Z Naturforsch [C] 1999; 54: 1075-83.
95. Su BN, Chai H, Mi Q, et al. Activity-guided isolation of cytotoxic constituents from the bark of Aglaia crassinervia collected in Indonesia. Bioorg Med Chem 2006; 14: 960-72.
96. Wu TS, Liou MJ, Kuoh CS, et al. Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia. J Nat Prod 1997; 60: 606-8.
97. Kim S, Salim AA, Swanson SM, Kinghorn AD. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemo-therapy. Anticancer Agents Med Chem 2006; 6: 319-45.
98. Zhu JY, Lavrik IN, Mahlknecht U, et al. The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities. Int J Cancer 2007; 121: 1839-46.
99. Hwang BY, Su BN, Chai H, et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem 2004; 69: 3350-8.
100. El Sous M, Khoo M, Holloway G, et al. Total synthesis of (-)-episilvestrol and (-)-silvestrol. Angew. Chemie Int Ed 2007; 46: 7835-8.
101. Gerard B, Cencic R, Pelletier J, Porco J. Enantioselective synthesis of the complex rocaglate (-)-silvestrol. Angew. Chemie Int Ed 2007; 46: 7831-4.
102. Adams TE, El Sous M, Hawkins BC, et al. Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4'-desmethoxyepisilvestrol. J Am Chem Soc 2009; 131: 1607-16.
103. Cencic R, Carrier M, Galicia-Vazquez G, et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009; 4: e5223.
104. Salim AA, Chai HB, Rachman I, et al. Constituents of the leaves and stem bark of Aglaia foveolata. Tetrahedron 2007; 63: 7926-34.
105. Baumann B, Bohnenstengel F, Siegmund D, et al. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T- cells. J Biol Chem 2002; 277: 44791-800.
106. Proksch P, Giaisi M, Treiber MK, et al. Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activity in T cells. J Immunol 2005; 174: 7075-84.
107. Mi Q, Kim S, Hwang BY, et al. Silvestrol regulates G2/M checkpoint genes independent of p53 activity. Anticancer Res 2006; 26: 3349-56.
108. Kim S, Hwang BY, Su BN, et al. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res 2007; 27: 2175-83.
109. Lucas DM, Edwards RB, Lozanski G, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009; 113: 4656-66.
110. Bordeleau ME, Robert F, Gerard B, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118: 1-11.
111. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955-60.
112. Hussain SR, Cheney CM, Johnson AJ, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007; 13: 2144-50.
113. Meurer-Grimes BM, Yu J, Vario GL. Therapeutic compounds and methods. U.S. Patent US6710075 B2 2004.
114. Hollingshead M, Roberson J, Decker W, et al. In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice. Antiviral Res 1995; 28: 265-79.
115. Baker DD, Chu M, Oza U, Rajgarhia V. The value of natural products to future pharmaceutical discovery. Nat Prod Rep 2007; 24: 1225-44.
116. Harvey AL. Natural products in drug discovery. Drug Discov Today 2008; 13: 894-901.
117. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-20.
118. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009; 325: 161-5.
119. Miller SJ, Clardy J. Natural products: Beyond grind and find. Nature Chem 2009; 1: 261-3.
120. Cragg GM, Kingston DGI, Newman DJ. In: Anticancer Agents from Natural Products. Boca Raton, FL, CRC Taylor & Francis, 2005.
121. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009; 109: 3012-43.
122. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-77.
123. Cragg GM, Newman DJ, Yang SS. Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J Nat Prod 2006; 69: 488-98.